

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 078883/0120	SERIAL NO. 09/522,798
INFORMATION DISCLOSURE CITATION Use several sheets if necessary)		APPLICANT Miles William CARROLL et al.	
		FILING DATE 3/24/2000	GROUP ART UNIT 1644-1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
MD	A1	5,118,672	06/92	Schinazi et al.	514	47	

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
MD	A2	99/15684	04/99	WIPO				
	A3	99/15683	04/99	WIPO				
	A4	89/07947	09/89	WIPO				
MD	A5	92/03568	03/92	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MD	A6	Guschlbauer et al., "Poly-2'-deoxy-2'-fluoro-cytidylic acid: enzymatic synthesis, spectroscopic Characterization and interaction with poly-inosinic acid" 1977 Nucleic Acids Res. 4:1933
	A7	Schibahara et al., "Site-directed cleavage of RNA" 1987 Nucleic Acids Res. 15:4403
	A8	Gershon et al., "The nucleotide sequence around the capripoxvirus thymidine kinase gene reveals a gene Shared specifically with leporipoxvirus" J. Gen. Virol. 70:525, 1989
	A9	Weir et al., "Nucleotide sequence of the vaccinia virus thymidine kinase gene and the nature of spontaneous Frameshift mutations" J. Virol. 46:530, 1983
	A10	Esposito et al., "Nucleotide sequence of the thymidine kinase gene region of monkeypox and variola viruses" Virology 135:561, 1984
	A11	Kilpatrick et al., "Cloning and physical mapping of yada monkey tumor virus DNA" Virology 143:399, 1985
	A12	Binns et al., "Comparison of a conserved region in fowlpox virus and vaccinia virus genomes and the translocation of the fowlpox virus thymidine kinase gene" J. Gen. Virol 69:1275, 1988
	A13	Schnitzlein et al., "A rapid method for identifying the thymidine kinase genes of avipoxviruses" J. Virological Method 20:341, 1988
MD	A14	Fathi et al., "Efficient targeted insertion of an unselected marker into the vaccinia virus genome" Virology 97-105, 1986

EXAMINER

/Marianne DiBrino/

DATE CONSIDERED

09/22/2006

- * EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PT 05449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 078883/0120	SERIAL NO. 09/533,798
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Miles William CARROLL et al.		10/774,176	
		FILING DATE 3/24/2000		GROUP ART UNIT 1644 1643	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
MD	A15	Graham et al., "A new technique for the assay of infectivity of human adenovirus 5 DNA" Virol. 52, 456-467, 1973			
	A16	Stralblinger et al., "Liposomes as carriers for intracellular delivery of nucleic acids" Methods in Enzymology, 101: 512-527 1983			
	A17	Studier et al., "Use of T7 RNA polymerase to direct expression of cloned genes" Methods in Enzymol. 185: 60-89, 1990			
	A18	Matthias et al., "Eukaryotic expression vectors for the analysis of mutant proteins" 1989 NAR 17, 6418			
	A19	Wootton & Federhen, "Statistics of local complexity in amino acid sequences and sequence database" 1993, Computers and Chemistry 17:149-163			
	A20	Myers et al., "Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein" 1994 J. Biol. Chem 169:9319-9324			
	A21	Starzynska et al., "Prognostic significance of 5T4 oncofetal antigen expression in colorectal" Br. J. Cancer 1994 May; 69(5):899-902			
	A22	Starzynska et al., "The expression of 5T4 antigen in colorectal and gastric carcinoma" Br. J. Cancer 1992 Nov; 66(5):867-869			
	A23	Hobbs et al., "polynucleotides containing 2'-amino-2'-deoxyribose and 2'-azido-2'-deoxyribose" 1973 Biochemistry 12:5138			
	A24	Starzynska et al., "5T4 oncofetal antigen in gastric carcinoma and its clinical significance" Eur J. Gastroenterol Hepatol 1998 Jun;10(6):479-484			
	A25	Carsberg et al., "Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells" 1996, Int J Cancer Sep 27; 68(1):84-92			
MD	A26	Yewdell et al., "TAP-independent delivery of antigenic peptides to the endoplasmic reticulum: therapeutic potential and insights into TAP-dependent antigen processing" 1998 J Immunotherapy 21:127-31			
	A27	Calvert et al., "Fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus induce neutralizing antibodies and reduce viremia in chickens" J. of Virol 67:3069-3076, 1993			
	A28	Carroll et al., "Construction and characterization of a triple recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen" 1998 J. Natl. Cancer Inst. 90(24):1881-1887			
	A29	Two bright new faces in gene therapy" Nature Biotechnology 1998 14, 658			
EXAMINER /Marianne DiBrino/			DATE CONSIDERED 09/22/2006		
<ul style="list-style-type: none"> EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant. 					

Form PTO-1549 (MODIFIED) MAY 13 2004 INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 078883/0120	SERIAL NO. 09/533,798
		APPLICANT Miles William CARROLL et al.		101 774,176	
		FILING DATE 3/24/2000		GROUP ART UNIT 1644	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	A30	Plaken et al., "Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes" 1991 Science 253:314-317			
MD	A31	Parker et al., "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains" 1994 J. Immunol. 152:163-175			
	A32	Fu et al., "An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope" 1998 J. Virol 72:1469-81			
	A33	Schedel et al., "Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier molecule" 1996 Intervirology 39:104-10			
	A34	Wolff and Trubetsky, "The embryonic period of nonviral gene delivery" 1998 nature Biotechnology 16:421-423			
	A35	Taylor et al., "Biological and immunogenic properties of a canarypox-vectored recombinant, ALVAC-RG (VCP65) in non-avian species" 1995 Vaccine 13:539-549			
	A36	Stannard et al., "Evidence for incomplete replication of a penguin poxvirus in cells of mammalian origin" J. Gen. Virol. 1998 79:1637-46			
	A37	Mackett et al., "Vaccinia virus: a selectable eukaryotic cloning and expression vector 1982 PNAS 79: 7415-7419			
	A38	Upton et al., "Identification and nucleotide sequence of the thymidine kinase gene of Shope fibroma virus" J. Virology 60:920, 1986			
	A39	Boyle et al., "Fowlpox virus thymidine kinase: nucleotide sequence and relationships to other thymidine kinases" Virology 156:355-365, 1987			
	A40	Lewis et al., "Human immunodeficiency virus infection of cells arrested in the cell cycle" 1992 EMBO J 11:3053-3058			
	A41	Lewis and Emerman "Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus" 1994 J. Virol. 68:510-516			
	A42	Mackett et al. "General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes" 1984, J. Virol. 49:857-864			
EXAMINER		/Marianne DiBrino/		DATE CONSIDERED 09/22/2006	
• EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.					

MAY 13 2004

Sheet 4 of 6

Form PTO-1449
(MODIFIED)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

078883/0120

SERIAL NO.

09/522,798

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

Miles William CARROLL et al.

FILING DATE

3/24/2000

GROUP ART UNIT

644 1543

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

A43

~~Hruby et al., "Fine structure analysis and nucleotide sequence of the vaccinia virus thymidine kinase gene"~~
PNAS 80:3411-3415, 1983

A44

~~Lybryn et al., "Comparison of the thymidine kinase genes from three orthopoxviruses" J. Gen. Virol.~~
73:3235-3240 1992

A45

~~Smith et al., "Vaccinia virus immune evasion" 1997, Immunol Rev. 159:137-154~~

A46

~~Jenkins et al., "Formation of reovirus particles by mammalian cells infected with recombinant fowlpox virus"~~
AIDS Research and Human Retroviruses 7:991-998, 1991

A47

~~Taylor et al., "Recombinant fowlpox virus inducing protective immunity in non-avian species" Vaccine 6:497-~~
503, 1988

A48

~~Sphener et al. and Boursnell et al., "Insertion of the fusion gene from newcastle disease virus into a non-~~
essential region in the terminal repeats of fowlpox virus and demonstration of protective immunity induced by
The recombinant" 1990 J. Gen. Virol. 71:621-628

A49

~~Nakano et al., "Molecular genetics of vaccinia virus: demonstration of marker rescue" Proc. Natl. Acad. Sci.~~
USA 79, 1593-1596, 1982

A50

~~Chakrabarti et al., "vaccinia virus expression vector: coexpression of β -galactosidase provides visual~~
screening of Recombinant virus plaques" Mol. Cell. Biol. 3403-3409, 1985

A51

~~Wigler et al., "Transformation of mammalian cells with genes from prokaryotes and eucaryotes" Cell 77:785,~~
1979

A52

~~Graessmann et al., "Microinjection of tissue culture cells" Meth. Enzymology 101, 402-492, 1983~~

A53

~~Franko et al., "Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia~~
virus recombinants" Mol Cell Biol 1918-1924, 1985

A54

~~Attenburger, W., Guter, C.P. and Attenburger J., "Partial deletion of the human host range gene in the~~
attenuated vaccinia virus MVA" 1989 Arch. Virol. 105, 15-27

EXAMINER

/Marianne DiBrino/

DATE CONSIDERED

09/22/2006

- EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 608; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 078883/0120		SERIAL NO. 09/333,798	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Miles William CARROLL et al.		10/794,176	
				FILING DATE 3/24/2000		GROUP ART UNIT 1644 1045	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A55	Neumann et al., "Gene transfer into mouse myoma cell by electroporation in high electric fields" EMBO J. 1, 841-845, 1982					
	A56	Schaffner, "Direct transfer of cloned genes from bacteria to mammalian cells" Proc. Natl. Acad. Sci. USA 77,2163-2167, 1980					
	A57	Nestle FO et al., "vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells" Nat. Med. 1998 Mar;4(3):328-32					
	A58	Attouch et al., "Issues in searching molecular sequence database" 1994 Nature Genetics 8:119-120					
	A59	Carroll & Moss, "Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line", 1997 Virology 238:198-211					
	A60	Kim GJ et al., "Dendritic cell infected with poxviruses encoding Mart 4/melan-a sensitive T Lymphocytes in vitro" J. Immunother, 1997 Jul;20(4):276-86					
	A61	Schneider et al., "enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara" 1998 Nat Med 4:397-402					
	A62	Chakrabarti et al., "Compact, synthetic, vaccinia virus early/late promoter for protein expression" 1997 Biotechniques 23:1094-1097					
	A63	Wyatt et al., "Development of replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model" 1996 Vaccine 14:1451-1458					
	A64	Butter et al., "A recombinant vector derived from the host range restricted and highly attenuated MVA strain Of vaccinia virus stimulates protective immunity in mice to influenza virus", 1994 Vaccine 12:1032-1040					
	A65	Carroll and Moss "E. coli β-glucuronidase (GUS) as a marker for recombinant vaccinia viruses" 1995 Biotechniques 19:352-355					
	A66	Hirsch et al., "Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV) infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara" 1996 J. Virol 70:3741-3752					
EXAMINER /Marianne DiBrino/				DATE CONSIDERED 09/22/2006			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 078883/0120	SERIAL NO. 09/533,788
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Miles William CARROLL et al.	01 774,176
				FILING DATE 3/24/2000	GROUP ART UNIT 1644
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	A67	Sutter and Moss, "Nonreplicating vaccinia vector efficiently expresses recombinant genes" 1992 Proc. Natl. Acad. Sci. USA 89:10847-10851			
	A68	Bronte et al., "Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine" 1997, Proc. Natl. Acad. Sci. USA 94(7):3183-3188			
	A69	Wyatt et al., "Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells" 1995 Virology 210:202-205			
MD	A70	Carroll et al., "Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model" 1997 Vaccine, 15:387-394			
	A71	Sutter et al., "Non-replication vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase" 1995 FEBS Lett. 371:9-12			
	A72	Overwijk et al., "gp100/pmel 17 is a murine tumor rejection antigen induction of "Self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand", (1998) J. Exp. Med. 188: 277-286			
	A73	Hole N. and Stern PL, "Isolation and characterization of 5T4, a tumor-associated antigen", (1990) Int. J. Cancer 45(1): 179-184			
EXAMINER	/Marianne DiBrino/			DATE CONSIDERED	09/22/2006
<p>• EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.</p>					

Form PTO-7449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE MAY 13 2004 INFORMATION DISCLOSURE CITATION Data Submitted to PTO: September 6, 2000		ATTY. DOCKET NO. 078883/0120	SERIAL NO. 09/333,790 101 774,176
		APPLICANT Miles William CARROLL and Kevin Alan MYERS	FILING DATE March 24, 2000
		GROUP ART UNIT 644 4642	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
MD	A1	EP-A-0198328	04/02/86	Europe				
MD	A2	EP-A-0110385	11/29/83	Europe				

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)			

EXAMINER /Marianne DiBrino/	DATE CONSIDERED 09/22/2006
--------------------------------	-------------------------------

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.



PTO/SB/08A (08-03)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/774,176
		Filing Date	February 6, 2004
		First Named Inventor	Carroll, Miles W.
		Art Unit	1644
		Examiner Name	Marianne NMN Dibrino
Sheet 1	of 2	Attorney Docket Number	021911-000510US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (# known)			
	AA	US-			
	AB	US-			
	AC	US-			
	AD	US-			
	AE	US-			
	AF	US-			
	AG	US-			
	AH	US-			
	AI	US-			
	AJ	US-			
	AK	US-			
	AL	US-			
	AM	US-			
	AN	US-			
	AO	US-			
	AP	US-			
	AQ	US-			
	AR	US-			
	AS	US-			
	AT	US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code* (if known)				
MD	AU	PCT	WO97/19183	A2	05/29/1997	Glaxo Group Limited		<input checked="" type="checkbox"/>
	AV							<input type="checkbox"/>
	AW							<input type="checkbox"/>
	AX							<input type="checkbox"/>
	AY							<input type="checkbox"/>
	AZ							<input type="checkbox"/>
	BA							<input type="checkbox"/>
	BB							<input type="checkbox"/>

Examiner Signature	/Marianne DiBrino/	Date Considered	09/22/2006
-----------------------	--------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/774,176
				<i>Filing Date</i>	February 6, 2004
				<i>First Named Inventor</i>	Carroll, Miles W.
				<i>Art Unit</i>	1644
				<i>Examiner Name</i>	Marianne NMN Dibrino
(use as many sheets as necessary)				<i>Attorney Docket Number</i>	021911-000510US
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MD	BC	CORREALE, Pierpaolo, et al. "Generation of Human Cytolytic T Lymphocyte Lines Directed Against Prostate-Specific Antigen (PSA) Employing a PSA Oligopeptide Peptide", <i>The Journal of Immunology</i> (1998) 161:3186-3194	
	BD	HODGE, James W., et al. "A Recombinant Vaccinia Virus Expressing Human Prostate-Specific Antigen (PSA): Safety and Immunogenicity in a Non-Human Primate", <i>Int. J. Cancer</i> (1995) 63:213-237	
	BE	HOLE, N., et al. "A 72 kD trophoblast glycoprotein defined by a monoclonal antibody", <i>Br. J. Cancer</i> (1998) 57:239-248	
	BF	IRVINE, Kari R., et al. "Synthetic Oligonucleotide Expressed by a Recombinant Vaccinia Virus Elicits Therapeutic CTL", <i>The Journal of Immunology</i> (1995) 154:4651-4657	
	BG	JACKSON, Ronald J., et al. "Infertility in Mice Induced by a Recombinant Ectromelia Virus Expressing Mouse Zona Pellucida Glycoprotein 3", <i>Biology of Reproduction</i> (1998) 58:152-159	
	BH	KASS, Erik, et al. "Induction of Protective Host Immunity to Carcinoembryonic Antigen (CEA), a Self-Antigen in CEA Transgenic Mice, by Immunizing with a Recombinant Vaccinia-CEA Virus", <i>Cancer Research</i> (1999) 59:676-683	
	BI	ROSATO, Antonio, et al. "CTL Response and Protection Against P815 Tumor Challenge in Mice Immunized with DNA Expressing the Tumor-Specific Antigen P815A", <i>Human Gene Therapy</i> (1997) 8:1451-1458	
	BJ	SANDA, Martin G., et al. "Recombinant Vaccinia-PSA (Prostvac) Can Induce a Prostate-Specific Immune Response in Androgen-Modulated Human Prostate Cancer", <i>Urology</i> (1999) 53:260-268	
	BK	SOUTHALL, P.J., et al. "Immunohistological distribution of 5T4 antigen in normal and malignant tissues", <i>Br. J. Cancer</i> (1990) 61:89-95	
	BL	TSANG, Kwong Y., et al. "Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine", <i>J. Natl. Cancer Inst.</i> (1995) 87(13):982-990	
MD	BM	WANG, Rong-Fu "Tumor Antigens Discovery: Perspectives for Cancer Therapy", <i>Molecular Medicine</i> (1997) 3(11):718-731	

Examiner Signature	/Marianne DiBrino/	Date Considered	09/22/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.